Topoisomerase I inhibitors: camptothecins and beyond, Nature Reviews Cancer, vol.24, issue.10, pp.789-802, 2006. ,
DOI : 10.1038/nrc1977
Polymorphisms Predictive for Pharmacokinetics and Treatment Outcome in Patients With Non???Small-Cell Lung Cancer Treated With Irinotecan and Cisplatin, Journal of Clinical Oncology, vol.24, issue.15, pp.2237-2281, 2006. ,
DOI : 10.1200/JCO.2005.03.0239
Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study, The Lancet Oncology, vol.10, issue.11, pp.1063-1072, 2009. ,
DOI : 10.1016/S1470-2045(09)70259-1
On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex, Biochemistry, vol.28, issue.11, pp.4629-4667, 1989. ,
DOI : 10.1021/bi00437a018
Point mutations in the topoisomerase I gene in patients with non-small cell lung cancer treated with irinotecan, Lung Cancer, vol.35, issue.3, pp.299-304, 2002. ,
DOI : 10.1016/S0169-5002(01)00425-1
New Topoisomerase I mutations are associated with resistance to camptothecin, Molecular Cancer, vol.10, issue.1, p.64, 2011. ,
DOI : 10.1016/j.jmb.2004.03.077
URL : https://hal.archives-ouvertes.fr/inserm-00602236
A multidrug resistance transporter from human MCF-7 breast cancer cells, Proceedings of the National Academy of Sciences, vol.95, issue.26, pp.15665-70, 1998. ,
DOI : 10.1073/pnas.95.26.15665
Associations ofABCB1, ABCC2, andABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer, Cancer, vol.10, issue.1, pp.138-185, 2007. ,
DOI : 10.1002/cncr.22760
ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases, International Journal of Cancer, vol.63, issue.6, pp.848-54, 2004. ,
DOI : 10.1002/ijc.20032
BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells, Biochemical Pharmacology, vol.60, issue.6, pp.831-838, 2000. ,
DOI : 10.1016/S0006-2952(00)00396-8
Transport of 7-Ethyl-10-hydroxycamptothecin (SN-38) by Breast Cancer Resistance Protein ABCG2 in Human Lung Cancer Cells, Biochemical and Biophysical Research Communications, vol.288, issue.4, pp.827-859, 2001. ,
DOI : 10.1006/bbrc.2001.5850
Wild-type breast cancer resistance protein (BCRP/ ABCG2) is a methotrexate polyglutamate transporter, Cancer Res, vol.63, pp.5538-5581, 2003. ,
Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells, Cancer Res, vol.61, pp.6635-6644, 2001. ,
High-Affinity Interaction of Tyrosine Kinase Inhibitors with the ABCG2 Multidrug Transporter, Molecular Pharmacology, vol.65, issue.6, pp.1485-95, 2004. ,
DOI : 10.1124/mol.65.6.1485
Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties, British Journal of Pharmacology, vol.7, issue.4 ,
DOI : 10.1111/j.1476-5381.2009.00383.x
Anticancer drug FL118 is more than a survivin inhibitor: Where is the Achilles' heel of cancer?, Am J Cancer Res, vol.4, pp.304-315, 2014. ,
A Novel Small Molecule FL118 That Selectively Inhibits Survivin, Mcl-1, XIAP and cIAP2 in a p53-Independent Manner, Shows Superior Antitumor Activity, PLoS ONE, vol.7, issue.9, p.45571, 2012. ,
DOI : 10.1371/journal.pone.0045571.t002
Hydrophilic Camptothecin Analogs That Form Extremely Stable Cleavable Complexes with DNA and Topoisomerase I, Cancer Research, vol.64, issue.18, pp.6679-83, 2004. ,
DOI : 10.1158/0008-5472.CAN-04-1885
A camptothecin-resistant DNA topoisomerase I mutant exhibits altered sensitivities to other DNA topoisomerase poisons, J Biol Chem, vol.270, pp.6141-6149, 1995. ,
Antitumor Activity of FL118, a Survivin, Mcl-1, XIAP, and cIAP2 Selective Inhibitor, Is Highly Dependent on Its Primary Structure and Steric Configuration, Molecular Pharmaceutics, vol.11, issue.2, pp.457-67, 2014. ,
DOI : 10.1021/mp4004282
FL118 Induces p53-Dependent Senescence in Colorectal Cancer Cells by Promoting Degradation of MdmX, Cancer Research, vol.74, issue.24, pp.7487-97, 2014. ,
DOI : 10.1158/0008-5472.CAN-14-0683
Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic, International Journal of Cancer, vol.96, issue.1, pp.146-51, 2004. ,
DOI : 10.1002/ijc.11528
Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C, Mol Cancer Ther, vol.1, pp.417-442, 2002. ,
Novel 7-Substituted Camptothecins with Potent Antitumor Activity, Journal of Medicinal Chemistry, vol.43, issue.21, pp.3963-3972, 2000. ,
DOI : 10.1021/jm000944z
Preclinical evaluation of the novel 7-substituted camptothecin Namitecan (ST1968) in paediatric tumour models, Cancer Chemotherapy and Pharmacology, vol.54, issue.6, pp.811-833, 2012. ,
DOI : 10.1007/s00280-012-1973-0
Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9- nitrocamptothecin, Cancer Res, vol.63, pp.3228-3261, 2003. ,
Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells, International Journal of Cancer, vol.47, issue.6, pp.921-928, 2004. ,
DOI : 10.1002/ijc.20216
An intravenous (i.v.) route-compatible formulation of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, improves FL118 antitumor efficacy and therapeutic index (TI), Am J Transl Res, vol.5, pp.139-54, 2013. ,
Cabazitaxel, Nature Reviews Drug Discovery, vol.363, issue.9, pp.677-685, 2010. ,
DOI : 10.1038/nrd3254
Chemical Modification of an Antitumor Alkaloid Camptothecin: Synthesis and Antitumor Activity of 7-C-Substituted Camptothecins., CHEMICAL & PHARMACEUTICAL BULLETIN, vol.39, issue.10, pp.2574-80, 1991. ,
DOI : 10.1248/cpb.39.2574
Camptothecin analogs with enhanced activity against human breast cancer cells. I. Correlation of potency with lipophilicity and persistence in the cleavage complex, Cancer Chemotherapy and Pharmacology, vol.37, issue.2, pp.135-179, 2006. ,
DOI : 10.1007/s00280-005-0007-6
Mesothelin Expression in Human Lung Cancer, Clinical Cancer Research, vol.13, issue.5, pp.1571-1576, 2007. ,
DOI : 10.1158/1078-0432.CCR-06-2161
Induction of Survivin Expression by Taxol (Paclitaxel) Is an Early Event, Which Is Independent of Taxol-mediated G2/M Arrest, Journal of Biological Chemistry, vol.279, issue.15, pp.15196-203, 2004. ,
DOI : 10.1074/jbc.M310947200
PBEQ-Solver for online visualization of electrostatic potential of biomolecules, Nucleic Acids Research, vol.36, issue.Web Server, pp.270-275, 2008. ,
DOI : 10.1093/nar/gkn314
CHARMM-GUI: A web-based graphical user interface for CHARMM, Journal of Computational Chemistry, vol.89, issue.11, pp.1859-65, 2008. ,
DOI : 10.1002/jcc.20945
The Electronegativity of Groups, The Journal of Physical Chemistry, vol.69, issue.10, pp.3284-91, 1965. ,
DOI : 10.1021/j100894a011
The Electronegativity of Multiply Bonded Groups, The Journal of Physical Chemistry, vol.70, issue.7, pp.2086-92, 1966. ,
DOI : 10.1021/j100879a003
REVISED METHOD FOR CALCULATION OF GROUP ELECTRONEGATIVITIES, Chemistry Letters, vol.11, issue.7, pp.1003-1009, 1982. ,
DOI : 10.1246/cl.1982.1003
Chemical Property Calculation through JavaScript and Applications in QSAR, Molecules, vol.4, issue.1, pp.16-27, 1999. ,
DOI : 10.3390/40100016
A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer, Journal of Clinical Oncology, vol.22, issue.1, pp.23-30, 2004. ,
DOI : 10.1200/JCO.2004.09.046
A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer, Annals of Oncology, vol.22, issue.8, pp.1798-804, 2011. ,
DOI : 10.1093/annonc/mdq652